Zhejiang Huahai Pharmaceutical (600521.SH): Received the drug registration certificate for Telmisartan Hydrochlorothiazide Tablets.
Hua Hai Pharmaceutical (600521.SH) announced that it has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Telmisartan Hydrochlorothiazide Tablets, which are used to treat primary hypertension.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that it has recently received the "Drug Registration Certificate" for Telmisartan and Hydrochlorothiazide Tablets issued by the National Medical Products Administration. Telmisartan and Hydrochlorothiazide Tablets are used for the treatment of essential hypertension.
According to relevant national policies, the production of Telmisartan and Hydrochlorothiazide Tablets approved under Category 4 of chemical drugs is considered equivalent to passing the consistency evaluation. The approval of this product further enriches the company's product line and helps enhance its market competitiveness.
Related Articles
HK Stock Market Move | LEGEND HOLDING (03396) rose over 6% following a positive earnings forecast, expecting a net profit attributable to equity holders in the first half to increase by no less than 186% year-on-year.
HK Stock Market Move | XUNCE (03317) surged over 18% as revenue driven by its token business significantly increased,.
HK Stock Market Move | TAI HING GROUP (06811) rose over 8% after announcing a profit alert, expecting a net profit attributable to shareholders of approximately HKD 72 million to HKD 78 million for the first half of the year.
HK Stock Market Move | LEGEND HOLDING (03396) rose over 6% following a positive earnings forecast, expecting a net profit attributable to equity holders in the first half to increase by no less than 186% year-on-year.
HK Stock Market Move | XUNCE (03317) surged over 18% as revenue driven by its token business significantly increased,.
HK Stock Market Move | TAI HING GROUP (06811) rose over 8% after announcing a profit alert, expecting a net profit attributable to shareholders of approximately HKD 72 million to HKD 78 million for the first half of the year.
RECOMMEND
